The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 19, 2023

Filed:

Oct. 30, 2020
Applicants:

Massachusetts Institute of Technology, Cambridge, MA (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Alexander K. Shalek, Cambridge, MA (US);

Peter Winter, Cambridge, MA (US);

David Weinstock, Boston, MA (US);

Mark Murakami, Boston, MA (US);

Scott Manalis, Cambridge, MA (US);

Andrew Navia, Cambridge, MA (US);

Jennyfer Galvez-Reyes, Cambridge, MA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 31/403 (2006.01); A61K 31/427 (2006.01); A61K 31/5383 (2006.01); A61K 31/44 (2006.01); A61P 35/02 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/403 (2013.01); A61K 31/427 (2013.01); A61K 31/44 (2013.01); A61K 31/5383 (2013.01); A61K 45/06 (2013.01); A61P 35/02 (2018.01); C07K 16/2887 (2013.01);
Abstract

Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.


Find Patent Forward Citations

Loading…